Phase II trial of perifosine +/- sorafenib in heavily pretreated patients with relapsed/refractory lymphomas
Phase of Trial: Phase II
Latest Information Update: 09 Dec 2014
At a glance
- Drugs Perifosine (Primary) ; Sorafenib
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 11 Dec 2012 Final data were presented at the American Society of Hematology annual meeting, according to an Aeterna Zentaris Inc media release.
- 26 Nov 2012 Status changed to completed based on information reported in an Aeterna Zentaris media release.
- 26 Nov 2012 Final trial data will be presented at the 2012 Annual Meeting of the American Society of Hematology (ASH-2012) according to an Aeterna Zentaris media release.